WuXi AppTec Sells China Clinical Research Business to Sharpen Focus
WuXi AppTec has agreed to sell its China-based clinical research services business, including WuXi Clinical and WuXi MedKey, to Hillhouse Investment Management.
WuXi AppTec
Delivering Quality with Speed for European Market
In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and the goals of the European expansion.
WuXi STA Opens new Parenteral Formulation Line
WuXi STA has started up a new parenteral formulation line at its drug product site in Wuxi City, China. The company’s second line for parenteral drug product clinical and commercial manufacturing to go on stream this year has an annual capacity of 10 million units.
WuXi Opens Lipid Nanoparticle Facility
WuXi STA has opened a sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi city, China, in response to rising demand for complex injection dosage forms.
WuXi Expands API Competence in Asia
WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a focal point.
Wuxi ATU Collaborates with Singapore’s BTI
WuXi Advanced Therapies (Wuxi ATU), US-based CDMO offshoot of WuXi AppTec, is joining up with Singapore’s Bioprocessing Technology Institute (BTI) to advance cell and gene therapy production in the Asia Pacific region.
WuXi AppTec Buys British CDMO Oxgene
China’s WuXi AppTec has acquired British gene therapy CDMO Oxgene, making the Oxford-based company a wholly owned subsidiary of the contract testing, development and manufacturing business unit for cell and gene therapies, WuXi Advanced Therapies. With the sale, Oxgene will retain its name.
